$UVFT is Ivy League
February 5th, 2010 at 9:14 am Posted by The Dean
If you’ve been paying attention to The Dean’s third ever Ivy League Stock Pick, $UVFT, you’d know that this stock has been gradually moving upward. In fact, for those students who were able to enter this penny stock around $0.25, $UVFT has been up as much as 52%, visiting $0.38 on more than one occasion.
The Dean believes $UVFT not only has the potential to turn up big in the fight against a third wave of H1N1 but the FDA approved UV400 Viraguard could also contribute to higher air quality in a number of places (e.g. schools, buildings, doctor’s offices, day care centers, churches, retail stores) and benefit the general public.
The Dean wants all of his students to remember that $UVFT is effective in killing H1N1, yes, but $UVFT’s UV400 Viraguard also delivers 99% effectiveness in eliminating viruses, bacteria, mold and allergens.
If you’ve done your homework on $UVFT, you’d find that the company’s flagship product can rid the air of Bacillus subtilis, Pseudomonas aeruginosa, Klebsiella pneumoniae, Staphylococcus aureus, Variola (smallpox), Adenovirus and SARS coronavirus.
The Dean thinks this list is quite impressive and $UVFT should not be pushed aside due to some investors thinking Swine Flu Frenzy is washed up. In fact, some areas of the U.S., most recently Michigan, are concerned about the hundreds of thousands of children who did not receive their second H1N1 vaccine dose—nevermind the millions who have yet to receive a first vaccine.
Nevertheless, The Dean believes in $UVFT’s ability to benefit people with respiratory problems, 300 million asthma sufferers, mold allergies, households with fungus control problems, and the general public by increasing indoor air quality.
